Therapeutic study of gomesina in mice with disseminated and vaginal candidiasis.

A gomesina é um peptídeo antimicrobiano catiônico, purificado dos hemócitos da aranha caranguejeira Acanthoscurria gomesiana. Possui amplo espectro de atividade contra bactérias, fungos, protozoários e células tumorais. Candida albicans é uma levedura comensal que faz parte da microbiota humana. O tratamento desta micose geralmente é feito com fluconazol, contudo casos de resistência vêm sendo reportados, com isso vários peptídeos antimicrobianos vêm sendo estudados a fim de se tornarem tratamentos alternativos. Este trabalho teve como objetivo avaliar a eficácia do tratamento com a gomesina em um modelo de candidíase disseminada e vaginal. O tratamento de gomesina foi eficaz no controle do fungo. Verificou-se um efeito imunomodulatório, pois seu tratamento aumentou as concentrações de IL-6, TNF-a e INF-g dos rins dos animais com candidíase disseminada. A gomesina não apresentou nenhum efeito tóxico para os animais. Os dados apresentados neste estudo reforçam o potencial da gomesina para ser um agente.The gomesin is a cationic antimicrobial peptide, purified from hemocytes of the spider Acanthoscurria gomesiana. It has a broad spectrum of activity against bacteria, fungi, protozoa and tumor cells. Candida albicans is commensal yeast that is part of the human microbiota. The treatment of this mycosis is usually done with fluconazole although cases of resistance have been reported. With the emergence of microorganisms resistance, several antimicrobial peptides have been studied in order to become alternative treatments. This study aimed to evaluate the effectiveness of treatment with gomesin in a model of disseminated and vaginal candidiasis. The treatment with gomesin showed to be effective in controlling the fungus. There was also found an immunomodulatory effect as its treatment increased concentrations of IL-6, TNF-a and INF-g in the kidneys of animals with disseminated candidiasis. The gomesin did not show any toxic effect to animals. The data presented in this study reinforce the potential of gomesin to be an antifungal agent

Paracoccidioides lutzii and other fungi of medical importance: development of therapeutic vaccine and alternative treatment with synthetic compounds in the control of systemic mycoses.

A maioria dos tratamentos antifúngicos são longos e não eficazes, portanto, há uma necessidade de pesquisa de novas alternativas. A fim de prospectar novos epitopos para uma vacina para Paracoccidioides lutzii e Cryptococcus spp.. Foi desenvolvido um sistema com o objetivo de purificar epitopos de macrófagos no contexto de MHCII. Além disso, houve pesquisa de epítopos na parede celular e sobrenadante de Paracoccidioides spp. A atividade antifúngica da miltefosina foi avaliada contra Paracoccicioides spp.. A miltefosina demonstrou atividade inibitória similar à anfotericina B. A atividade fungicida ocorreu em baixas concentrações, se observou alterações ultraestruturais e formação de melanina. A atividade do C7a in vitro e in vivo contra Candida spp. foi analisada. Os resultados mostraram atividade fungicida em valores baixos. Além disso, foi visto inibição da formação de hifas / pseudohifas e alterações morfológicas. Os ensaios in vivo demonstraram uma diminuição significativa na infecção em um modelo de candidíase vaginal e sistêmica.Most of antifungal treatments are not completely effective or long, thus there is a need to search new alternatives. In order to prospect new epitopes for a vaccine to Paracoccidioides lutzii and Cryptococcus spp.. A system was developed with the purpose of purify epitopes from macrophages in the context of MHCII. Also, a search for epitopes in the cell wall and supernatant of Paracoccidioides spp. was done. The antifungal activity of miltefosina was evaluated against Paracoccicioides spp.. Miltefosine demonstrated inhibitory activity similar to amphotericin B. Fungicidal activity occurred at low concentrations, ultrastructural alterations and melanin production were observed. The activity of C7a in vitro and in vivo against Candida spp. was analyzed. The results showed fungicidal activity at low values. Also, it was revealed that inhibition of formation of hyphae/pseudohyphae and morphological alterations. In vivo assays demonstrated a significant decrease of fungal border of intravaginal and intravenous infected mice

Search for CPCP violation in D0^0→\to KS0^0_\mathrm{S}KS0^0_\mathrm{S} decays in proton-proton collisions at s\sqrt{s} = 13 TeV

International audienceA search is reported for charge-parity D$^0$$\to$ K$^0_\mathrm{S}$K$^0_\mathrm{S}$$CP$ violation in D$^0$$\to$ K$^0_\mathrm{S}$K$^0_\mathrm{S}$ decays, using data collected in proton-proton collisions at $\sqrt{s}$ = 13 TeV recorded by the CMS experiment in 2018. The analysis uses a dedicated data set that corresponds to an integrated luminosity of 41.6 fb$^{-1}$, which consists of about 10 billion events containing a pair of ẖadrons, nearly all of which decay to charm hadrons. The flavor of the neutral D meson is determined by the pion charge in the reconstructed decays D$^{*+}$$\to$ D$^0\pi^+$ and D$^{*-}$$\to$ D$^0\pi^-$. The D$^0$$\to$ K$^0_\mathrm{S}$K$^0_\mathrm{S}$$CP$ asymmetry in D$^0$$\to$ K$^0_\mathrm{S}$K$^0_\mathrm{S}$ is measured to be $A_{CP}$( K$^0_\mathrm{S}$K$^0_\mathrm{S}$) = (6.2 $\pm$ 3.0 $\pm$ 0.2 $\pm$ 0.8)%, where the three uncertainties represent the statistical uncertainty, the systematic uncertainty, and the uncertainty in the measurement of the D$^0$ $\to$ K$^0_\mathrm{S}$K$^0_\mathrm{S}$ $CP$ asymmetry in the D$^0$ $\to$ K$^0_\mathrm{S}\pi^+\pi^-$ decay. This is the first D$^0$ $\to$ K$^0_\mathrm{S}$K$^0_\mathrm{S}$ $CP$ asymmetry measurement by CMS in the charm sector as well as the first to utilize a fully hadronic final state